TNFRSF17-eiwit (C-His, mens)

TNFRSF17

BCM, BCMA, CD269, TNFRSF13A

C-His

< 1.0 EU per μg protein as determined by the LAL method.

1.Flow cytometric analysis of anti-BCMA CAR expression. 5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:125 dilution of PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and negative control protein. Non-transduced 293 cells were used as a control (left) . PE signal was used to evaluate the binding activity (QC tested) . 2.Binding activity of PE-conjugated BCMA protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested) . 3.Flow cytometric analysis of anti-BCMA CAR expression. HEK293 cells were lentivirally transduced with anti-BCMA CAR. Non-transduced HEK293 cells were used as a control (shown on the left) . 2 μL (1 test) of site-specifically PE-conjugated human BCMA protein from two vendors (competitor A and SINO) was used. The results demonstrated that SINO’s 10620-H86H-SP has a much higher fluorescence intensity than that of the competitor (Routinely tested) . 4.Flow cytometric analysis using PE conjugated BCMA protein. 5e5 of anti-BCMA CAR-293 cells were stained with PE-conjugated human BCMA protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) . Non-transduced 293 cells were used as a control (Black Histogram) . The protein exhibited stable performance after multiple freeze-thaw cycles (5, 10 cycles)

Met1-Ala54

The protein has a predicted molecular mass of 11.8 kDa.

Human